Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

医学 内科学 临床终点 队列 肿瘤科 结直肠癌 进行性疾病 奥拉帕尼 无进展生存期 胃肠病学 癌症 外科 疾病 临床试验 总体生存率 化学 聚ADP核糖聚合酶 基因 聚合酶 生物化学
作者
Deepti Behl,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Laura Catherine Farrington,Oxana Crysler,Elie G. Dib,Herbert Leon Duvivier,Michael J. Hall,John Stuart Salmon,Olatunji B. Alese,Alissa S. Marr,Isa Ngirailemesang,Latha Polavaram,Ramya Thota,Eddy S. Yang,Raegan O'Lone,Gina N. Grantham,Susan Halabi,Richard L. Schilsky
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (4_suppl): 122-122 被引量:1
标识
DOI:10.1200/jco.2023.41.4_suppl.122
摘要

122 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of pts with CRC with ATM mut treated with O are reported. Methods: Eligible pts had advanced CRC with ATM mut, no standard treatment (tx) options, measurable disease, ECOG Performance Status (PS) 0-2, and adequate organ function. Genomic testing was done in CLIA-certified, CAP-accredited labs. Recommended dosing for O was 300 mg twice daily (tablets) or 400 mg twice daily (capsules) until disease progression. Primary end point was disease control (DC), defined as complete or partial (PR) response per RECIST v. 1.1, or stable disease (SD) at 16+ weeks (wks) (SD16+). Simon 2-stage design tested the null DC rate of 15% vs. 35% (power = 0.85; α = 0.10). If ≥2 of 10 pts in stage 1 has DC, 18 more pts are enrolled; otherwise, cohort is closed for futility. If ≥7 of 28 pts has DC, the null DC rate is rejected. Secondary end points were progression-free survival (PFS), overall survival (OS), duration of response (DOR), duration of SD, and safety. DOR is defined as time from the pt’s first documented objective response (OR) until progressive disease (PD). Duration of SD is defined as time from start of tx to PD. Results: 30 pts with CRC and ATM mut were enrolled from Sept 2016 to Aug 2019. 3 pts were not included in efficacy outcomes: 2 pts had no post-baseline tumor evaluation; 1 pt was found to be ineligible after receiving 1 dose. 1 PR ( ATM P938fs*11 and RAD50 variant of unknown significance (VUS); DOR was 18.6 wks) and 3 SD16+ ( ATM R1875*, splice site 4237-11_4241del16, E522*; duration of SD was 19.7, 25.3 and 27.0 wks, respectively) were observed for DC rate of 23% (95% CI, 6% to 39%) and OR rate of 4% (95% CI, 0.1% to 19%). The null DC rate was not rejected (p=0.38). 6/30 pts had a BRCA2 co-alteration, but none of these pts achieved OR or SD16+; no pts had a BRCA1 co-alteration; aside from the pt with PR and RAD50 VUS, only 1 other pt who achieved OR or SD16+ had a co-alteration among the other homologous recombination-related genes examined ( ATR VUS). 7 pts had ≥1 Grade 3 adverse or serious adverse event (SAE) at least possibly related to O, including urinary tract infection, white blood cell decreased, febrile neutropenia (SAE), anemia (1 SAE), lung infection (SAE), fatigue (SAE), and nausea (SAE). Conclusions: Monotherapy O does not show sufficient antitumor activity in pts with advanced CRC with ATM mut to warrant further study. Clinical trial information: NCT02693535 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幽默枫发布了新的文献求助10
刚刚
H_完成签到 ,获得积分10
刚刚
zhaung发布了新的文献求助10
刚刚
刚刚
wchwei123发布了新的文献求助10
刚刚
刚刚
wearelulu完成签到,获得积分10
1秒前
apricity199的应助被qww采纳,获得10
1秒前
黑心茶叶蛋完成签到,获得积分10
1秒前
Chengdi完成签到,获得积分10
2秒前
gzslwddhjx发布了新的文献求助10
3秒前
今天发布了新的文献求助10
3秒前
3秒前
思源的应助被寒冷的天亦采纳,获得10
3秒前
风与诗完成签到 ,获得积分10
3秒前
阳静发布了新的文献求助10
4秒前
白云黑土的应助被无限初丹采纳,获得10
4秒前
dawwf发布了新的文献求助10
4秒前
桐桐的应助被YUAN采纳,获得20
4秒前
一米阳光完成签到,获得积分20
4秒前
略略略爱发布了新的文献求助10
4秒前
星空完成签到,获得积分10
4秒前
现代斌完成签到,获得积分10
4秒前
5秒前
tao发布了新的文献求助10
5秒前
大鹅完成签到,获得积分10
5秒前
6秒前
wwwy007完成签到,获得积分10
6秒前
千千完成签到,获得积分10
6秒前
白云黑土的应助被tt采纳,获得10
6秒前
刘承昭发布了新的文献求助10
6秒前
lx完成签到 ,获得积分10
7秒前
Lucas的应助被曹牛牛采纳,获得10
7秒前
fortuna发布了新的文献求助10
7秒前
二指弹完成签到 ,获得积分10
7秒前
7秒前
8秒前
长阶词完成签到,获得积分10
8秒前
我是老大的应助被duduqiang采纳,获得10
8秒前
李嘉怡完成签到,获得积分20
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741